Patents by Inventor David Y. Liu

David Y. Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240293511
    Abstract: The disclosure provides methods for the treatment and/or prevention of iron overload diseases such as hereditary hemochromatosis.
    Type: Application
    Filed: June 14, 2022
    Publication date: September 5, 2024
    Inventors: Suneel Kumar GUPTA, David Y. LIU, Nishit Bachulal MODI, Frank Horace VALONE
  • Publication number: 20240209024
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: August 7, 2023
    Publication date: June 27, 2024
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Brian Troy FREDERICK, Jie ZHANG, Adam STEPHENSON, Mark Leslie SMYTHE, Roopa TARANATH, David Y. LIU
  • Publication number: 20240016895
    Abstract: The disclosure provides compositions and methods for the treatment and/or prevention of sickle cell disease.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 18, 2024
    Inventors: David Y. LIU, Gregory Thomas BOURNE, Roopa TARANATH, Li ZHAO
  • Publication number: 20230063321
    Abstract: The invention relates to methods of treating inflammatory bowel diseases, including with engineered peptides (e.g. peptide monomers and dimers comprising disulfide or thioether intramolecular bonds) that bind ?4?7 integrin. In one aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering to the subject an ?4?7 integrin antagonist, wherein the antagonist is administered to the patient orally at a dose of about 100 mg to about 500 mg, once or twice daily, wherein the antagonist is a peptide dimer compound comprising two peptides, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 2, 2023
    Inventors: Suneel Kumar Gupta, Nishit Bachulal Modi, Xiaoli Cheng, David Y. Liu, Larry C. Mattheakis
  • Publication number: 20220372099
    Abstract: The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.
    Type: Application
    Filed: September 3, 2020
    Publication date: November 24, 2022
    Inventors: David Y. LIU, Gregory Thomas BOURNE, Roopa TARANATH, Suneel Kumar GUPTA, Nishit Bachulal MODI
  • Publication number: 20210061872
    Abstract: The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.
    Type: Application
    Filed: September 3, 2020
    Publication date: March 4, 2021
    Inventors: David Y. Liu, Gregory Thomas Bourne, Roopa Taranath, Suneel Kumar Gupta, Nishit Bachulal Modi
  • Patent number: 8530404
    Abstract: The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: September 10, 2013
    Assignee: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Patent number: 8314059
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: November 20, 2012
    Assignee: FibroGen, Inc.
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Y. Liu, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang
  • Publication number: 20120039882
    Abstract: The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided.
    Type: Application
    Filed: October 21, 2011
    Publication date: February 16, 2012
    Applicant: FibroGen, Inc.
    Inventors: Ingrid Langsetmo Parobok, Christopher T. Jacob, David Y. Liu
  • Patent number: 8088381
    Abstract: The present invention relates to methods for treating impaired cardiac function. Methods for treating various physiological and pathological features associated with cardiac dysfunction by administering an agent that inhibits the expression or activity of connective tissue growth factor (CTGF) are provided.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: January 3, 2012
    Assignee: FibroGen, Inc.
    Inventors: Ingrid Langsetmo Parobok, Christopher T. Jacob, David Y. Liu
  • Publication number: 20110015223
    Abstract: The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are refractory to treatment with recombinant human erythropoietin (EPO) are encompassed herein.
    Type: Application
    Filed: August 16, 2010
    Publication date: January 20, 2011
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Publication number: 20100291098
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Application
    Filed: June 3, 2010
    Publication date: November 18, 2010
    Applicant: FibroGen, Inc.
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Y. Liu, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang
  • Publication number: 20100204269
    Abstract: The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 12, 2010
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Patent number: 7713986
    Abstract: The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: May 11, 2010
    Assignee: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Publication number: 20080254487
    Abstract: The present invention provides compounds and agents that modulate CTGF-mediated cell adhesion and/or binding of CTGF to cells. The invention further provides assays that may be used to identify additional modulators of CTGF-mediated cell adhesion and CTGF binding to cells, and assays that may be used to identify compounds or agents that modulate interaction of CTGF with HSPGs.
    Type: Application
    Filed: January 14, 2005
    Publication date: October 16, 2008
    Applicant: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, David Y. Liu, Irina Aizman
  • Patent number: 7345045
    Abstract: The invention is directed to methods to inhibit TGF-? and/or p38-? kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar? is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: March 18, 2008
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Publication number: 20070292433
    Abstract: The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.
    Type: Application
    Filed: June 15, 2006
    Publication date: December 20, 2007
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Publication number: 20070293575
    Abstract: The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are refractory to treatment with recombinant human erythropoietin (EPO) are encompassed herein.
    Type: Application
    Filed: June 15, 2006
    Publication date: December 20, 2007
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Patent number: 7268139
    Abstract: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: September 11, 2007
    Assignee: Scios, Inc.
    Inventors: Andrew A. Protter, David Y. Liu, Patrick O'Connor
  • Patent number: 7189739
    Abstract: The invention is directed to compounds of the formula and the pharmaceutically acceptable salts thereof wherein Ar1 is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1–4C), halo, or lower alkoxy (1–4C); X1 is CO or an isostere thereof; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; n is 0 or 1; Z is CH or N; X2 is CH, CH2 or an isostere thereof; and Ar2 consists of one or two phenyl moieties directly coupled to X2 and optionally substituted by halo, nitro, alkyl (1–6C), CN or CF3, or by RCO, COOR, CONR2, NR2, OR or SR, wherein R is H or alkyl (1–6C) or by phenyl, itself optionally substituted by the foregoing substituents; with the proviso that if Z is N, X1 is CO, and Ar1 is indole, Ar1 must be coupled to X1 through the 2-, 5-, 6- or 7-position. These compounds are useful in the treatment of conditions associated with inflammation.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: March 13, 2007
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, David Y. Liu, George F. Schreiner, John A. Lewicki, John J. Perumattam